TACT411
Pharmaceutical compound
From Wikipedia, the free encyclopedia
TACT411 is a monoamine transporter modulator and serotonin 5-HT1B receptor modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder.[1][2] It is being developed by Tactogen.[1][2] As of the first quarter of 2025, the drug is in the preclinical research stage of development.[1][2] The exact chemical structure of TACT411 does not yet appear to have been disclosed, but it may be a benzofuran like 5-MAPB, 6-MAPB, BK-5-MAPB, or BK-6-MAPB.[3]
Other namesTACT-411
| Clinical data | |
|---|---|
| Other names | TACT-411 |
| Drug class | Monoamine transporter modulator; Serotonin 5-HT1B receptor modulator |
